Accelr8 Technology Corporation is a public company, and our stock trades on the Amex: AXK.
 |
| Crystal Research Associates, LLC: Executive Informational Overview® (EIO®) |
1.4MB Adobe® Acrobat®
PDF file 56 pages |
|
| Crystal Research Associates, LLC: EIO® update, 23-Jun-2006 |
256KB Adobe® Acrobat®
PDF file 12 pages |
|
| Crystal Research Associates, LLC: EIO® update, 07-Feb-2007 |
344KB Adobe® Acrobat®
PDF file 12 pages |
|
| SEC filings |
Edgar |
|
| Google™ FInance stock chart |
Google |
|
| Yahoo® Finance stock chart |
Yahoo |
|
|
|
|
Key Business Points
The BACcelr8r™
- The point of sale is the ICU Medical Director. Mission-critical with very high urgency and awareness (>40,000 attributable deaths/year, US only). Bypasses the Clinical Lab as decision driver, removes the product from the (potential) commodity perception. No turf wars since it does not threaten any departmental revenues nor need to displace any installed base. Relatively price insensitive because of the unique ICU positioning.
- Hospital CEO/CFOs see "hard dollar" loss avoidance. Their exposure per confirmed case is $10-40K each, and recovery is abysmal. Example: Barnes-Jewish in St. Louis now recovers only ~5% of their cost for managing a nosocomial infection. It's about to get worse because CMS (Medicare) is now effectively ending reimbursement for nosocomial infections.
- The experts in the industry (to the extent they will reveal), leading Clinical Microbiologists, and leading ICU physicians are aware of no other product in development even attempting to deliver <8-hour antibiotic resistance analysis. Lots of effort on rapid ID based on genetic tests for screening carriers, but nothing to support treatment decisions with active infections. Genetic methods are quite unlikely to provide Rx guidance in any reasonable time frame.
